Inverness, Ill and Oklahoma City, OK (PRWEB) November 18, 2013
GMSbiotech, Inc. (GMS), creator of novel microarray-based diagnostic solutions for personalized medicine and transplantation compatibility and Pure Transplant Solutions, LLC, (PTS) a leader in soluble HLA reagents production and application development, today announced a partnership that will leverage the GMS platform and the PTS soluble HLA technology including its suite of over 200 Class I and Class II alleles, anticipated to grow to 300 alleles over the duration of the project.
"We have invested over $15M in the last 14 years to develop the PTS reagent technology and GMS has invested over $10M in the last 10 years developing their platform," said Thomas Harlan, CEO Pure Transplant Solutions, "Leveraging our combined infrastructures and unique strengths will allow us to develop a novel technology solution while lowering the risk, time and costs normally associated with these types of ventures."
"We are excited about this collaboration and look forward to the development of a prototype which we hope to distribute by Q3 2014 to select ASHI certified labs for beta testing," said Dr. Krishna Jayaraman, President & CEO of GMSbiotech.
About GMSbiotech, Inc.
GMSbiotech (GMS) is a privately held company focusing on its patented microarray platform to develop accurate and affordable genetic and serology tests. With the company’s disruptive technology in Raw Sample Genotyping (RSG) combined with its microarray platform, complex genetic testing experienced by labs across the field has been substantially simplified into a routine, everyday low-cost component of clinical diagnostics and public health screening. The company is commercializing its technologies with an initial focus on transplantation diagnostics. For additional information on the company please visit http://www.gmsbiotech.com.
About Pure Transplant Solutions, LLC
Pure Transplant Solutions, L.L.C. ("PTS") is a subsidiary of Pure Protein L.L.C, a company that has developed and patented several soluble HLA protein technology methods and immunology tools for therapeutic and diagnostic applications in solid organ and stem cell transplantation, cross-reactive antibody screening, and major autoimmune diseases. Pure Protein was formed in 1999 to commercialize research developed by Dr. William Hildebrand at the University of Oklahoma Health Sciences Center. Pure Transplant Solutions was formed in 2003 to use HLA protein to develop diagnostics, devices, and therapeutics to help eliminate transplant rejection. To learn more visit http://www.pureproteinllc.com.
Pure Protein and its subsidiaries are funded and managed by innovation solutions company Emergent Technologies, Inc. For more information visit http://www.emergenttechnolgogies.com.